Engineered regulatory T Cells for the treatment of GVHD and inflammatory diseases

A novel cell based therapy to combat disordered inflammation. Using a novel method, CD4+ and CD8+ regulatory T cells have been engineered to over express both FOXP3 and Helios without suppression of either product. Efficacy of the eTregs has been shown…
  • A novel cell-based therapy to combat disordered inflammation. Using a novel method, CD4+ and CD8+ regulatory T cells have been engineered to over-express both FOXP3 and Helios without suppression of either product. Efficacy of the Tregs has been shown in vitro and in a humanized model of graft versus host disease (GVHD)

Website

https://cmh.flintbox.com/technologies/22F1674852654D619065CFB645E591D8

Advantages

  • The CD4+ and CD8+ eTregs exhibit stable expression, with about 98% of FOXP3+Helios+ cells retaining high FOXP3 and Helios expression 21 days post-transduction and 12 days in vivo in mice
  • Can separate CD4+ and CD8+ cells if desired
  • The novel method produces larger quantities of eTregs more rapidly by eliminating the need to isolate and expand populations of naturally occurring Tregs
  • First reported generation of CD8+ Tregs with suppressive activity

Potential Applications

  • Biologic for the treatment of GVHD in organ and stem cell transplant patients
  • Biologic for the treatment of diseases in which it is desirable to reduce inflammatory immune responses. Examples would include type I diabetes, multiple sclerosis, allograft/transplant rejection, inflammatory bowel disease, lupus, rheumatoid arthritis, and other chronic inflammatory diseases

Contact Information

Name: Marcia Molina

Email: mimolina@cmh.edu

Phone: 785-341-8112 (mobile)